A new study helps physicians understand how patients analyze the costs and benefits of RA treatments so that they can better engage patients in shared decision-making.
Tapering DMARDs: Where are we now?
The promise of drug-free RA remission is appealing, but many questions remain. Explore answers at Biologics Summit VII in April 2017.